Outcome of intensive integrated intervention in participants with impaired glucose regulation in China

Advances in Therapy

Volumn 28, Issue 6, 2011, Pages 511-519

  Lu, Yan Hui ^a   Lu, Ju Ming ^a   Wang, Shu Yu ^b   Li, Chun Lin ^a   Zheng, Run Ping ^b   Tian, Hui ^a   Wang, Xian Ling ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing Hypertension Federation   (China)

Author keywords

China; impaired glucose regulation; intensive integrated intervention; prevention; type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; METFORMIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE; BODY MASS; CHINA; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEALTH EDUCATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHINA; DIET; EXERCISE; FEMALE; GLUCOSE INTOLERANCE; HEALTH BEHAVIOR; HEALTH EDUCATION; HUMANS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROGRAM EVALUATION; TRIGLYCERIDES;

EID: 79958185431     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0022-4     Document Type: Article

References (22)

1. Wild S, Sicree R, Roglic G, King H, Green A. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053.
2. Yang WY, Lu JM, Weng JP, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090-1101.
3. Harris MI. Impaired glucose tolerance: prevalence and conversion to NIDDM. Diabetic Med. 1996;13(Suppl 2):S9-S11.
4. The DECODE Study Group. Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-404.
5. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care. 1999;22:920-924. (Pubitemid 29241045)
6. Zimme PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity and demography. Diabetes Care. 1995;18:1050-1064.
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
8. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419. (Pubitemid 15018832)
9. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
10. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes prevention program research group reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. (Pubitemid 34437694)
11. Lindstrom J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J. The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003;26:3230-3236. (Pubitemid 37466880)
12. Mensink M, Feskens EJM, Saris WHM, Debruin TWA, Blaak EE. Study on lifestyle intervention and impaired glucose tolerance Maastricht (SLIM): preliminary results after one year. Int J Obes Relat Metab Disord. 2003;27:377-384. (Pubitemid 36384876)
13. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077.
14. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-494.
15. Li CL, Pan CY, Lu JM, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med. 1999;16:477-481.
16. Yang WY, Lin LX, Qi JW, et al. The preventive effect of Acarbose and Metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentral prospective study. Chin J Endocrinol Metab. 2001;17:131-134.
17. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose for the prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese subjects with impaired glucose tolerance. Nippon Rinsho. 2010;68:873-881.
18. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (Troglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials. 1998;19:217-231. (Pubitemid 28191975)
19. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096-1105.
20. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes. 1999;48:2197-2203. (Pubitemid 29521850)
21. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, Defronzo RA. Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes. 2006;55:1430-1435. (Pubitemid 44195383)
22. DeFronzo RA, Banerji MA, Bray GA, et al. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia. 2010;53:435-445.